Concerns related to the coronavirus disease 2019 pandemic in adult patients with atopic dermatitis and psoriasis treated with systemic immunomodulatory therapy: a Danish questionnaire survey
Open Access
- 11 August 2020
- journal article
- letter
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (12) , E773-E776
Abstract
Patients with moderate‐to‐severe atopic dermatitis (AD) or psoriasis often require systemic immunomodulatory therapy. The uncertainty of the potential of these therapies to increase the risk of more serious illness due to Coronavirus disease 2019 (COVID‐19) may have caused anxiety and led to treatment discontinuation. Therefore, we conducted an anonymous questionnaire on concerns of COVID‐19 in patients with AD or psoriasis treated with systemic immunomodulatory therapy.Keywords
This publication has 5 references indexed in Scilit:
- Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID‐19Journal of the European Academy of Dermatology and Venereology, 2020
- The impact of the COVID ‐19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experienceBritish Journal of Dermatology, 2020
- A survey of psoriasis patients on biologics during COVID-19: a single centre experienceJournal of Dermatological Treatment, 2020
- Should biologics for psoriasis be interrupted in the era of COVID-19?Journal of the American Academy of Dermatology, 2020
- COVID-19: risk for cytokine targeting in chronic inflammatory diseases?Nature Reviews Immunology, 2020